Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.47
TSRO's Cash-to-Debt is ranked lower than
76% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. TSRO: 1.47 )
Ranked among companies with meaningful Cash-to-Debt only.
TSRO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.47  Med: 5.96 Max: No Debt
Current: 1.47
1.47
No Debt
Equity-to-Asset 0.29
TSRO's Equity-to-Asset is ranked lower than
85% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TSRO: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
TSRO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.34 Max: 0.75
Current: 0.29
0.29
0.75
Debt-to-Equity 1.76
TSRO's Debt-to-Equity is ranked lower than
91% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. TSRO: 1.76 )
Ranked among companies with meaningful Debt-to-Equity only.
TSRO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.21  Med: 1.15 Max: 1.76
Current: 1.76
0.21
1.76
Debt-to-EBITDA -0.94
TSRO's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. TSRO: -0.94 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TSRO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.94  Med: -0.59 Max: -0.36
Current: -0.94
-0.94
-0.36
Piotroski F-Score: 3
Altman Z-Score: -0.31
Beneish M-Score: 1.21
WACC vs ROIC
10.55%
-4957.49%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -214.72
TSRO's Operating Margin % is ranked lower than
59% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. TSRO: -214.72 )
Ranked among companies with meaningful Operating Margin % only.
TSRO' s Operating Margin % Range Over the Past 10 Years
Min: -5754.9  Med: -616.54 Max: -214.72
Current: -214.72
-5754.9
-214.72
Net Margin % -222.15
TSRO's Net Margin % is ranked lower than
61% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. TSRO: -222.15 )
Ranked among companies with meaningful Net Margin % only.
TSRO' s Net Margin % Range Over the Past 10 Years
Min: -6135.44  Med: -645.01 Max: -222.15
Current: -222.15
-6135.44
-222.15
ROE % -112.87
TSRO's ROE % is ranked lower than
78% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. TSRO: -112.87 )
Ranked among companies with meaningful ROE % only.
TSRO' s ROE % Range Over the Past 10 Years
Min: -234.91  Med: -124.74 Max: -77.35
Current: -112.87
-234.91
-77.35
ROA % -65.34
TSRO's ROA % is ranked lower than
71% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. TSRO: -65.34 )
Ranked among companies with meaningful ROA % only.
TSRO' s ROA % Range Over the Past 10 Years
Min: -96.09  Med: -70.25 Max: -38.24
Current: -65.34
-96.09
-38.24
ROC (Joel Greenblatt) % -5308.36
TSRO's ROC (Joel Greenblatt) % is ranked lower than
81% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. TSRO: -5308.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TSRO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -36654.6  Med: -13072.88 Max: -5308.36
Current: -5308.36
-36654.6
-5308.36
3-Year EBITDA Growth Rate -22.60
TSRO's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. TSRO: -22.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TSRO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -42.3  Med: -30.15 Max: -10.7
Current: -22.6
-42.3
-10.7
3-Year EPS without NRI Growth Rate -24.20
TSRO's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. TSRO: -24.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TSRO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40.7  Med: -31.55 Max: -11.7
Current: -24.2
-40.7
-11.7
GuruFocus has detected 3 Warning Signs with Tesaro Inc TSRO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TSRO's 30-Y Financials

Financials (Next Earnings Date: 2018-05-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

TSRO Guru Trades in Q1 2017

Vanguard Health Care Fund 642,725 sh (New)
George Soros 1,700 sh (New)
Steven Cohen 501,800 sh (+1595.27%)
Paul Tudor Jones 4,028 sh (+67.76%)
Leon Cooperman 25,000 sh (unchged)
Steven Cohen 394,100 sh (unchged)
Pioneer Investments 107,480 sh (-23.78%)
» More
Q2 2017

TSRO Guru Trades in Q2 2017

Ron Baron 10,041 sh (New)
Paul Tudor Jones 22,822 sh (+466.58%)
Pioneer Investments 317,753 sh (+195.64%)
Vanguard Health Care Fund 1,027,035 sh (+59.79%)
Steven Cohen 150,000 sh (unchged)
Leon Cooperman Sold Out
George Soros Sold Out
Steven Cohen 25,000 sh (-95.02%)
» More
Q3 2017

TSRO Guru Trades in Q3 2017

Jim Simons 61,400 sh (New)
Vanguard Health Care Fund 1,586,035 sh (+54.43%)
Ron Baron 13,128 sh (+30.74%)
Steven Cohen 100,000 sh (unchged)
Paul Tudor Jones Sold Out
Pioneer Investments 104,982 sh (-66.96%)
Steven Cohen 3,200 sh (-87.20%)
» More
Q4 2017

TSRO Guru Trades in Q4 2017

Paul Tudor Jones 8,273 sh (New)
Jim Simons 357,400 sh (+482.08%)
Vanguard Health Care Fund 2,996,631 sh (+88.94%)
Steven Cohen Sold Out
Ron Baron Sold Out
Pioneer Investments 7,677 sh (-92.69%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:TSRO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-12-31 Add 88.94%0.25%$76.37 - $126.82 $ 51.98-47%2,996,631
Ron Baron 2017-12-31 Sold Out 0.01%$76.37 - $126.82 $ 51.98-47%0
Vanguard Health Care Fund 2017-09-30 Add 54.43%0.16%$109.05 - $142 $ 51.98-58%1,586,035
Ron Baron 2017-09-30 Add 30.74%$109.05 - $142 $ 51.98-58%13,128
Vanguard Health Care Fund 2017-06-30 Add 59.79%0.12%$136.01 - $155.73 $ 51.98-64%1,027,035
Ron Baron 2017-06-30 New Buy0.01%$136.01 - $155.73 $ 51.98-64%10,041
Leon Cooperman 2017-06-30 Sold Out 0.15%$136.01 - $155.73 $ 51.98-64%0
George Soros 2017-06-30 Sold Out 0.01%$136.01 - $155.73 $ 51.98-64%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:LOXO, SHSE:603233, NAS:LGND, NAS:ARRY, XKRX:086900, LSE:ABC, LSE:BTG, XKRX:084990, NAS:AAAP, XTER:MOR, HKSE:00570, SZSE:000990, NAS:CLVS, SZSE:002603, SZSE:300347, XSWX:IDIA, NAS:ACAD, SHSE:600161, NAS:FGEN, SZSE:300009 » details
Traded in other countries:T8S.Germany,
Headquarter Location:USA
Tesaro Inc is an oncology-focused biopharmaceutical company. It focuses on developing treatments for cancer.

Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Top Ranked Articles about Tesaro Inc

New Research Coverage Highlights MPLX LP, TESARO, LKQ, Cytokinetics, Keysight Technologies, and Charles River Laboratories International — Consolidated Revenues, Company Growth, and Expectations for 2018
TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018
TESARO Summarizes TSR-042 Clinical Data Presented at AACR
TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
TESARO LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Tesaro Incorporated To Contact The Firm
EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against TESARO, Inc. - TSRO
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tesaro Incorporated of Class Action Lawsuit and Upcoming Deadline - TSRO
Research Report Identifies TESARO, Brunswick, Brooks Automation, Infinity Pharmaceuticals, Edison International, and Anthem with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
TSRO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Tesaro, Inc. and a Lead Plaintiff Deadline of March 19, 2018 (TSRO)

Ratios

vs
industry
vs
history
PB Ratio 11.35
TSRO's PB Ratio is ranked lower than
86% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. TSRO: 11.35 )
Ranked among companies with meaningful PB Ratio only.
TSRO' s PB Ratio Range Over the Past 10 Years
Min: 8.73  Med: 14.87 Max: 26.18
Current: 11.35
8.73
26.18
PS Ratio 12.62
TSRO's PS Ratio is ranked lower than
57% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TSRO: 12.62 )
Ranked among companies with meaningful PS Ratio only.
TSRO' s PS Ratio Range Over the Past 10 Years
Min: 12.51  Med: 115.11 Max: 29065
Current: 12.62
12.51
29065
EV-to-EBIT -5.58
TSRO's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. TSRO: -5.58 )
Ranked among companies with meaningful EV-to-EBIT only.
TSRO' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.5  Med: -11.9 Max: -5
Current: -5.58
-25.5
-5
EV-to-EBITDA -5.69
TSRO's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. TSRO: -5.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
TSRO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.8  Med: -12.05 Max: -5.1
Current: -5.69
-25.8
-5.1
EV-to-Revenue 11.82
TSRO's EV-to-Revenue is ranked lower than
53% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. TSRO: 11.82 )
Ranked among companies with meaningful EV-to-Revenue only.
TSRO' s EV-to-Revenue Range Over the Past 10 Years
Min: 11.6  Med: 118.4 Max: 24675.3
Current: 11.82
11.6
24675.3
Current Ratio 4.74
TSRO's Current Ratio is ranked higher than
54% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. TSRO: 4.74 )
Ranked among companies with meaningful Current Ratio only.
TSRO' s Current Ratio Range Over the Past 10 Years
Min: 4.74  Med: 10.61 Max: 11.8
Current: 4.74
4.74
11.8
Quick Ratio 4.39
TSRO's Quick Ratio is ranked higher than
54% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. TSRO: 4.39 )
Ranked among companies with meaningful Quick Ratio only.
TSRO' s Quick Ratio Range Over the Past 10 Years
Min: 4.39  Med: 10.61 Max: 11.8
Current: 4.39
4.39
11.8
Days Inventory 257.91
TSRO's Days Inventory is ranked lower than
81% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. TSRO: 257.91 )
Ranked among companies with meaningful Days Inventory only.
TSRO' s Days Inventory Range Over the Past 10 Years
Min: 257.91  Med: 611.65 Max: 943.29
Current: 257.91
257.91
943.29
Days Sales Outstanding 87.30
TSRO's Days Sales Outstanding is ranked lower than
68% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. TSRO: 87.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
TSRO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.97  Med: 61.38 Max: 87.3
Current: 87.3
38.97
87.3
Days Payable 32.20
TSRO's Days Payable is ranked lower than
69% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. TSRO: 32.20 )
Ranked among companies with meaningful Days Payable only.
TSRO' s Days Payable Range Over the Past 10 Years
Min: 32.2  Med: 624.96 Max: 8869.5
Current: 32.2
32.2
8869.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.70
TSRO's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. TSRO: -14.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TSRO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -56  Med: -16.3 Max: -14.1
Current: -14.7
-56
-14.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 94.51
TSRO's Price-to-Net-Cash is ranked lower than
96% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. TSRO: 94.51 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TSRO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.05  Med: 11.88 Max: 150.67
Current: 94.51
4.05
150.67
Price-to-Net-Current-Asset-Value 16.19
TSRO's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. TSRO: 16.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TSRO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.01  Med: 11.46 Max: 30.96
Current: 16.19
4.01
30.96
Price-to-Tangible-Book 14.68
TSRO's Price-to-Tangible-Book is ranked lower than
84% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. TSRO: 14.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TSRO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.98  Med: 11.27 Max: 29.21
Current: 14.68
3.98
29.21
Price-to-Median-PS-Value 0.11
TSRO's Price-to-Median-PS-Value is ranked higher than
95% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. TSRO: 0.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TSRO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.96 Max: 4.55
Current: 0.11
0.11
4.55
Earnings Yield (Greenblatt) % -17.97
TSRO's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. TSRO: -17.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TSRO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.8  Med: -8.35 Max: -3.9
Current: -17.97
-19.8
-3.9

More Statistics

Revenue (TTM) (Mil) $223.33
EPS (TTM) $ -9.19
Beta1.34
Volatility32.89%
52-Week Range $50.67 - 168.92
Shares Outstanding (Mil)54.80

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 508 955 1,550
EBIT (Mil $)
EBITDA (Mil $) -263 -112 85
EPS ($) -5.37 1.02 6.23
EPS without NRI ($) -5.37 1.02 6.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}